References
- Dorrell MI, Aguilar E, Scheppeke L, Barnett FH, Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc. Natl Acad. Sci. USA104, 967–972 (2007).
- Brown DM, Kaiser PK, Michels M et al.; on behalf of the ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med.355, 1432–1434 (2006).
- Rosenfeld PJ, Brown DM, Heier JS et al, on behalf of the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med.355, 1419–1431 (2006).
- Gragoudas ES, Adamis AP, Cunnigham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med.351(27), 2805–2816 (2004).
- Sherris D. Ocular drug development – future directions. Angiogenesis10, 71–76 (2007).
- Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina25, 11–118 (2005).
- Schmidt-Eurfurth U, Scholtzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Nauman GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci.44, 4473–4480 (2003).
- Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis10, 141–148 (2007).
- Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina26, 988–993 (2006).
- Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina27, 133–140 (2007).